Emmaus Life Sciences (EMMA) stock price, revenue, and financials

Emmaus Life Sciences market cap is $56.8 m, and annual revenue was $1.32 m in FY 2018

$56.8 M

EMMA Mkt cap, 15-Sept-2020

$6.1 M

Emmaus Life Sciences Revenue Q3, 2019
Emmaus Life Sciences Gross profit (Q3, 2019)5.9 M
Emmaus Life Sciences Gross profit margin (Q3, 2019), %97.1%
Emmaus Life Sciences Net income (Q3, 2019)-26.1 M
Emmaus Life Sciences EBIT (Q3, 2019)-3.6 M
Emmaus Life Sciences Cash, 30-Sept-201913.5 M
Emmaus Life Sciences EV43.9 M

Emmaus Life Sciences Income Statement

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

197.8k184.3k214.1k190.8k22.7k20.9k31.0k24.7k20.7k21.1k22.2k31.9k40.4k122.0k459.9k391.7k387.1k460.1k6.1m

Cost of goods sold

37.8k39.2k35.9k35.5k31.4k35.6k38.8k37.6k29.4k5.2k1.1k1.8k1.2k1.2k1.4k1.5k3.7k3.8k16.2k84.9k298.3k244.2k225.1k296.3k178.0k

Gross profit

160.0k145.1k178.2k155.3k21.6k19.1k29.8k23.5k19.3k19.6k18.5k28.1k24.2k37.1k161.6k147.5k162.0k163.8k5.9m

Gross profit Margin, %

81%79%83%81%95%91%96%95%93%93%83%88%60%30%35%38%42%36%97%

Sales and marketing expense

366.6k330.0k315.0k226.0k91.5k80.1k83.4k91.5k93.4k105.6k89.7k175.2k31.1k123.2k133.0k158.1k105.7k191.8k292.1k667.2k638.0k182.6k151.9k199.4k1.8m

R&D expense

181.8k725.0k

General and administrative expense

1.1m1.1m1.1m916.7k461.3k749.2k653.2k521.5k469.0k533.1k441.8k408.3k409.4k377.1k370.6k428.3k1.0m934.2k966.8k1.8m1.7m2.5m2.4m2.4m7.0m

Operating expense total

1.6m1.6m1.6m1.4m552.8k829.3k736.6k613.0k562.4k638.7k800.8k798.3k585.1k646.4k709.3k828.8k1.5m1.4m1.6m2.8m2.8m3.1m2.8m2.8m9.5m

EBIT

(1.4m)(1.4m)(1.4m)(1.3m)(698.9k)(1.1m)(1.2m)(963.9k)(940.7k)(1.0m)(779.2k)(779.2k)(555.3k)(622.9k)(690.0k)(809.2k)(1.4m)(1.4m)(1.6m)(2.8m)(2.6m)(2.9m)(2.7m)(2.7m)(3.6m)

EBIT margin, %

(733%)(775%)(662%)(658%)(3433%)(3728%)(1791%)(2522%)(3333%)(3835%)(6468%)(4451%)(3847%)(2259%)(572%)(744%)(693%)(583%)(59%)

Interest expense

2.1m1.5m1.1m767.4k598.4k432.1k183.3k1.0k600.01.3k51.4k54.6k65.9k700.0239.6k487.9k2.5k1.4k1.9k13.7k24.8k23.8k22.9k23.4k

Pre tax profit

873.4k(2.7m)(8.4m)3.6m(960.3k)(1.5m)(1.3m)140.3k(941.3k)(1.0m)(870.5k)(694.6k)(535.3k)(3.4m)(142.7k)(1.4m)(1.4m)(1.4m)(1.6m)(2.8m)(2.7m)(2.9m)(2.7m)(2.7m)(26.1m)

Income tax expense

900.01.1k800.01.6k1.0k1.8k3.2k800.0800.0300.01.8k30.6k16.3k1.9k2.3k25.0k

Net Income

873.4k(2.7m)(8.4m)3.6m(973.3k)(1.5m)(1.3m)135.1k(942.0k)(1.0m)(874.6k)(696.3k)(536.8k)(3.5m)(142.7k)(1.4m)(1.4m)(1.5m)(1.6m)(2.8m)(2.7m)(2.9m)(2.7m)(2.7m)(26.1m)

Emmaus Life Sciences Balance Sheet

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

910.7k113.1k169.6k20.4k821.1k717.2k671.6k663.0k783.8k63.9k445.7k310.0k141.8k823.8k440.2k430.8k1.0m1.8m409.3k2.7m2.4m2.6m1.5m1.2m13.5m

Accounts Receivable

50.0k34.2k38.8k33.4k17.6k18.4k12.1k18.4k7.1k5.8k9.0k5.4k11.9k3.8k6.8k3.2k3.2k7.2k6.0k81.1k218.6k137.4k120.0k154.4k1.9m

Prepaid Expenses

67.1k48.9k113.4k77.4k17.8k109.6k103.4k32.7k100.4k97.1k26.6k114.7k98.9k55.3k58.9k78.0k17.4k17.3k29.9k67.0k82.6k195.3k146.6k181.2k1.2m

Inventories

7.5m

Current Assets

1.3m400.3k645.8k131.2k871.6k847.0k790.2k714.1k891.3k166.8k481.3k430.1k252.6k906.8k617.6k606.8k1.7m2.3m535.7k2.8m2.8m3.1m1.8m1.5m51.8m

PP&E

34.0k30.5k28.6k24.2k15.2k12.6k19.1k14.5k12.5k10.6k7.0k5.3k2.8k800.07.7k8.8k10.4k90.7k85.3k136.4k143.1k127.0k98.8k87.7k163.0k

Goodwill

1.4m1.4m1.4m1.4m1.4m44.0k

Total Assets

1.4m461.8k704.9k185.3k909.8k882.1k831.3k749.6k924.2k197.3k507.1k453.7k273.1k924.3k659.9k706.4k1.8m2.4m1.2m4.5m4.5m4.8m3.4m3.1m56.5m

Accounts Payable

804.8k731.8k890.9k774.1k841.5k833.4k817.1k744.2k736.4k521.6k720.0k1.1m1.0m1.0m466.5k728.8k970.7k7.4m

Short-term debt

5.9k6.2k6.2k5.7k4.7k4.4k7.0k6.7k5.6k4.6k3.3k3.4k2.2m1.6k1.7k1.2k58.3k1.2k1.3k1.3k1.3k1.3k1.4k1.4k15.0m

Current Liabilities

10.5m14.3m22.6m18.1m14.6m12.5m11.9m1.6m1.4m1.5m1.5m3.6m3.9m1.6m1.7m1.9m1.7m1.9m2.2m1.7m2.0m1.3m1.6m1.9m35.2m

Long-term debt

11.8k8.6k7.2k6.1k3.9k2.7k7.9k4.8k4.1k3.3k1.5m1.9m5.4k5.0k21.3k4.1k3.7k559.7k569.0k580.9k597.1k606.5k4.9m

Non-Current Liabilities

11.8k8.6k7.2k6.1k3.9k2.7k7.9k4.8k4.1k3.3k1.5m700.05.9m5.6m6.3m21.3k6.1k3.7k667.0k690.0k713.1k714.6k728.4k39.5m

Total Debt

17.7k14.8k13.4k11.8k8.6k7.1k14.9k11.5k9.7k7.9k1.5m1.9m2.2m1.6k7.1k6.2k79.6k5.3k5.0k561.0k570.3k582.2k598.5k607.9k617.3k

Total Liabilities

10.5m14.3m22.6m18.1m14.6m12.5m11.9m1.6m1.4m1.6m3.1m3.6m3.9m7.6m7.3m8.2m1.7m1.9m2.2m2.4m2.7m2.0m2.3m2.6m74.7m

Common Stock

56.1k56.2k1.9k1.9k2.1k29.8k49.8k96.1k100.5k100.6k101.7k101.7k101.7k102.4k102.7k107.5k2.3k2.5k2.5k4.4k4.4k6.3k7.6k8.9k47.0k

Preferred Stock

1.1k1.1k1.1k1.1k

Additional Paid-in Capital

30.4m31.1m31.5m31.8m32.9m36.5m(38.3m)55.5m56.7m56.9m57.4m57.5m57.6m59.3m59.5m60.0m70.1m72.0m72.0m80.5m82.9m86.7m89.8m91.9m199.4m

Retained Earnings

(39.5m)(45.0m)(53.4m)(49.7m)(46.6m)(48.1m)(49.5m)(56.4m)(57.4m)(58.4m)(60.1m)(60.8m)(61.3m)(66.0m)(66.2m)(67.5m)(70.0m)(71.4m)(73.0m)(78.4m)(81.1m)(83.6m)(87.6m)(89.9m)(216.9m)

Total Equity

(9.1m)(13.8m)(21.9m)(17.9m)(13.7m)(11.6m)(11.1m)(833.3k)(507.6k)(1.4m)(2.6m)(3.1m)(3.6m)(6.7m)(6.6m)(7.5m)84.4k526.8k(953.1k)2.1m1.8m2.7m1.1m512.1k(18.2m)

Debt to Equity Ratio

0.9 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

-0.1 x0 x0 x0 x-0.1 x-0.1 x-0.1 x-0.9 x-1.8 x-0.1 x-0.2 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x21.2 x4.6 x-1.3 x2.1 x2.5 x1.8 x3.1 x6.1 x-3.1 x

Emmaus Life Sciences Cash Flow

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(6.2m)(2.7m)(11.1m)(7.5m)(973.3k)(2.5m)(3.8m)135.1k(807.0k)(1.8m)(874.6k)(1.6m)(2.1m)(3.5m)(3.6m)(4.9m)(1.4m)(2.9m)(4.5m)(2.8m)(5.4m)(8.0m)(2.4m)(4.6m)(59.6m)

Depreciation and Amortization

8.7k4.0k9.1k14.0k4.0k6.0k8.5k2.8k5.4k7.8k2.2k4.4k6.0k1.4k2.7k3.9k8.0k18.1k33.1k23.3k57.5k87.7k30.2k60.3k98.0k

Accounts Receivable

(1.1k)20.2k15.6k21.0k(5.2k)(6.0k)300.08.2k19.5k20.8k300.03.9k(2.6k)8.0k5.0k8.6k1.9k(2.1k)(900.0)(18.1k)(156.2k)(76.5k)(59.9k)(97.4k)(548.0k)

Inventories

(2.8m)

Accounts Payable

75.4k54.1k307.4k1.3m(136.3k)(34.4k)(8.8k)(244.2k)(244.7k)(101.5k)(118.1k)31.8k1.2k(63.8k)(81.6k)(109.2k)88.3k316.8k397.6k(38.6k)112.4k(409.8k)417.1k559.6k4.9m

Cash From Operating Activities

(3.2m)(997.0k)(1.9m)(2.2m)(554.7k)(1.3m)(2.1m)(1.1m)(1.9m)(2.6m)(783.2k)(1.3m)(1.7m)(607.5k)(1.3m)(2.0m)(765.8k)(1.6m)(2.7m)(2.4m)(4.7m)(7.4m)(1.7m)(3.8m)(5.1m)

Purchases of PP&E

(1.0k)(2.8k)(1.6k)(84.8k)(87.1k)(28.1k)(55.2k)(55.2k)(4.1k)(9.1k)(55.0k)

Cash From Investing Activities

(19.7k)(23.1k)(25.5k)(25.5k)1.4k1.4k1.4k1.5k(10.0k)(68.5k)(3.7k)(88.4k)(230.0k)(334.7k)(361.8k)(361.8k)(4.1k)(9.1k)(1.5m)

Long-term Borrowings

(3.8k)(1.5k)(2.9k)(4.5k)(1.6k)(3.1k)(4.2k)(1.7k)(3.5k)(5.3k)(1.2k)(1.9k)(2.7k)(800.0)(2.0k)(2.9k)(300.0)(600.0)(900.0)(300.0)(600.0)(900.0)(300.0)(600.0)(3.4m)

Cash From Financing Activities

4.1m1.0m2.0m2.2m1.4m2.0m2.7m464.3k1.4m1.4m(1.2k)413.1k612.3k999.2k1.4m2.1m1.5m3.1m3.0m(16.1k)2.1m5.0m(8.6k)1.8m3.0m

Net Change in Cash

848.7k19.7k76.2k(73.0k)813.4k709.5k663.9k(610.6k)(489.8k)(1.2m)(794.9k)(930.6k)(1.1m)391.7k8.1k(1.3k)730.2k1.4m91.1k(2.8m)(3.0m)(2.8m)(1.8m)(2.1m)(3.5m)

Interest Paid

1.8k4.4k6.8k800.01.2k2.6k1.0k1.7k3.3k900.01.5k2.7k800.01.3k2.4k2.5k200.05.8k3.0k4.7k6.4k1.2k2.0k1.2m

Income Taxes Paid

1.3k900.0900.02.0k800.0800.0800.01.6k2.6k4.3k3.2k4.0k4.7k300.0300.0300.01.8k32.4k48.7k1.9k1.9k2.3k242.0k

Emmaus Life Sciences Ratios

USDQ3, 2011

Financial Leverage

-0.1 x